PBPK Model and Dose Adjustment for Imipenem in Pediatric Patients with Renal Impairment

A physiologically based pharmacokinetic model for the antibiotic imipenem, validated with fold error <2 between predicted and observed parameters. The model predicts exposure in pediatric patients with mild, moderate, and severe renal impairment and recommends optimized dosing regimens via Monte Carlo simulations. The dataset, authored by Chen Feng and last updated in May 2026, is shared under a CC-BY-4.0 license.

Use Cases

• Validate PBPK model predictions for imipenem exposure based on the described fold error validation method.
• Simulate optimized dosing regimens for pediatric patients with renal impairment using the described Monte Carlo simulation approach.
• Analyze the impact of prolonged infusion times (30 min to 3 h) on pharmacodynamic target attainment.
• Compare predicted AUC ratios (1.05-fold to 2.14-fold) for children with varying degrees of renal impairment against healthy children.

Strengths

• Model validation is explicitly quantified with a fold error criterion of <2.
• Provides specific dose recommendations (e.g., 7-15 mg/kg every 6 hours) for different patient subgroups based on simulation results.
• Includes predictions for three distinct clinical scenarios: mild, moderate, and severe renal impairment.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale statistical modeling.
• The primary data file is a 1.6 MB DOCX document, which may require extraction or conversion for computational analysis.

Provenance

Source

figshare

Collection Method

PBPK modeling and simulation using GastroPlus™ software, validated against observed pharmacokinetic parameters.

Time Range

null

Freshness

Last updated 2026-05 08 05:54:20; freshness should be verified.

Geography

null